These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16792440)

  • 1. PP-ICONS--another tool to help interpret asthma utilization studies.
    Crownover BK
    J Manag Care Pharm; 2006 May; 12(4):341-2. PubMed ID: 16792440
    [No Abstract]   [Full Text] [Related]  

  • 2. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy.
    Allen-Ramey FC; Bukstein D; Luskin A; Sajjan SG; Markson LE
    J Manag Care Pharm; 2006 May; 12(4):310-21. PubMed ID: 16792437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care utilization determined from administrative claims analysis for patients who received inhaled corticosteroids with either montelukast or salmeterol.
    Markson LE; Bukstein DA; Luskin AT
    J Manag Care Pharm; 2006; 12(6):486-7; author reply 487-9. PubMed ID: 16925457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is "more effective asthma control"?
    O'Brien K; Bukstein D
    J Allergy Clin Immunol; 2001 Jun; 107(6):1107-9. PubMed ID: 11398094
    [No Abstract]   [Full Text] [Related]  

  • 5. Eczema and race as combined determinants for differential response to step-up asthma therapy.
    Malka J; Mauger DT; Covar R; Rabinovitch N; Lemanske RF; Spahn JD; Strunk RC; Zeiger RS; Morgan WJ; Szefler SJ
    J Allergy Clin Immunol; 2014 Aug; 134(2):483-5. PubMed ID: 24835502
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety.
    Lenney W; McKay AJ; Tudur Smith C; Williamson PR; James M; Price D;
    Health Technol Assess; 2013 Feb; 17(4):1-218. PubMed ID: 23380178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retained strength of expired albuterol and montelukast pharmaceuticals.
    Abourashed EA; Kutty RG; Bevry M; Hoffmann P
    Ann Allergy Asthma Immunol; 2022 Feb; 128(2):222-223. PubMed ID: 34678427
    [No Abstract]   [Full Text] [Related]  

  • 8. In patients with asthma that is not well controlled with inhaled steroids, does salmeterol (Serevent) or montelukast (Singulair) offer better symptom relief?
    Cash R; Blonski J
    J Fam Pract; 2001 Sep; 50(9):802. PubMed ID: 11674917
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral montelukast versus inhaled salmeterol to prevent exercise-induced bonchonconstriction.
    Brestel EP
    Ann Intern Med; 2000 Sep; 133(5):392; author reply 392-3. PubMed ID: 10979887
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of pharmacist counseling in patients hospitalized with acute exacerbation of asthma.
    Stiegler KA; Yunker NS; Crouch MA
    Am J Health Syst Pharm; 2003 Mar; 60(5):473-6. PubMed ID: 12635454
    [No Abstract]   [Full Text] [Related]  

  • 11. Invalid and irrelevant comparisons: apples or oranges?
    Currie GP; Carter K
    Ann Allergy Asthma Immunol; 2006 Feb; 96(2):379. PubMed ID: 16498865
    [No Abstract]   [Full Text] [Related]  

  • 12. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.
    Price DB; Ben-Joseph RH; Zhang Q
    Respir Med; 2001 Jan; 95(1):83-9. PubMed ID: 11207023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral montelukast versus inhaled salmeterol to prevent exercise-induced bronchoconstriction.
    Grieco AJ; Burstein-Stein J
    Ann Intern Med; 2000 Sep; 133(5):392; author reply 392-3. PubMed ID: 10979888
    [No Abstract]   [Full Text] [Related]  

  • 14. [What is the role of montelukast in asthma treatment?].
    Aksu K; Aksu F
    Tuberk Toraks; 2020 Sep; 68(3):328-330. PubMed ID: 33295731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Montelukast and airway remodeling in children with chronic persistent asthma: an open study.
    Pifferi M; Caramella D; Ragazzo V; De Marco E; Pietrobelli A; Boner AL
    Pediatr Allergy Immunol; 2004 Oct; 15(5):472-3. PubMed ID: 15482525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.
    Balkrishnan R; Nelsen LM; Kulkarni AS; Pleasants RA; Whitmire JT; Schechter MS
    J Asthma; 2005 Feb; 42(1):35-40. PubMed ID: 15801326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
    Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
    Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
    O'Connor RD; Nelson H; Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
    Pharmacoeconomics; 2004; 22(12):815-25. PubMed ID: 15294013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.
    Wilson AM; Dempsey OJ; Sims EJ; Lipworth BJ
    Chest; 2001 Apr; 119(4):1021-6. PubMed ID: 11296164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of add-on therapy to inhaled fluticasone propionate in children with asthma: residual volume and exhaled nitric oxide as outcome measures.
    Verini M; Peroni DG; Piacentini GL; Nicodemo A; Rossi N; Bodini A; Chiarelli F; Boner AL
    Allergy Asthma Proc; 2007; 28(6):691-4. PubMed ID: 18201433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.